Abstract
Following the first small non-coding RNA identification in 1993, accumulated knowledge on the biogenesis, homeostasis and functional roles of microRNAs in different physiological and pathophysiological conditions has been discovered. MicroRNAs act through epigenetic regulation of gene expression. MiR-34a is a member of the MiR-34 family that is involved in p53 pathways, and is implicated in cell death/survival signaling. MiR-34a is associated with G1 cell cycle arrest, senescence and apoptosis, thereby possessing a tumor suppressor activity. Deregulation of MiR-34a has been reported in several types of cancers. MiR-34a downregulation has been correlated with cancer multidrug resistance (MDR), which is a major challenge for successful cancer chemotherapy. MiR-34a mimetic agents have been shown to attenuate drug resistance in different cancer cell lines. This review focuses on the in vitro, experimental and clinical findings dealing with the role of miR-34a downregulation in MDR, and potential therapeutic opportunities arising from this role of miR-34a.
Keywords: Cancer, chemotherapy, MicroRNA, miR-34a, multidrug resistance.
Current Pharmaceutical Design
Title:MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance
Volume: 22 Issue: 7
Author(s): Morteza Ghandadi and Amirhossein Sahebkar
Affiliation:
Keywords: Cancer, chemotherapy, MicroRNA, miR-34a, multidrug resistance.
Abstract: Following the first small non-coding RNA identification in 1993, accumulated knowledge on the biogenesis, homeostasis and functional roles of microRNAs in different physiological and pathophysiological conditions has been discovered. MicroRNAs act through epigenetic regulation of gene expression. MiR-34a is a member of the MiR-34 family that is involved in p53 pathways, and is implicated in cell death/survival signaling. MiR-34a is associated with G1 cell cycle arrest, senescence and apoptosis, thereby possessing a tumor suppressor activity. Deregulation of MiR-34a has been reported in several types of cancers. MiR-34a downregulation has been correlated with cancer multidrug resistance (MDR), which is a major challenge for successful cancer chemotherapy. MiR-34a mimetic agents have been shown to attenuate drug resistance in different cancer cell lines. This review focuses on the in vitro, experimental and clinical findings dealing with the role of miR-34a downregulation in MDR, and potential therapeutic opportunities arising from this role of miR-34a.
Export Options
About this article
Cite this article as:
Ghandadi Morteza and Sahebkar Amirhossein, MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance, Current Pharmaceutical Design 2016; 22 (7) . https://dx.doi.org/10.2174/1381612822666151209153729
DOI https://dx.doi.org/10.2174/1381612822666151209153729 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Photodynamic Therapy using Carbohydrate Conjugated Porphyrins
Drug Design Reviews - Online (Discontinued) Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry Cytoprotection and Immunomodulation in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Sera/Organ Lysates of Selected Animals Living in Polluted Environments Exhibit Cytotoxicity against Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry A Century of Thioxanthones: Through Synthesis and Biological Applications
Current Medicinal Chemistry Nutritional and Therapeutic Potential of Garlic and Onion (Allium sp.)
Current Nutrition & Food Science Cordycepin Suppresses Integrin/FAK Signaling and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry The Anti-Oxidant Properties of Isothiocyanates: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Genetic Predisposition to Neonatal Tumors
Current Pediatric Reviews The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets Radioimmunotherapy of Metastatic Prostate Cancer with <sup>177</sup>Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody
Current Radiopharmaceuticals MicroRNA-203: Tumor Suppression and Beyond
MicroRNA Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Current Topics in Medicinal Chemistry Autologous Formalin-Fixed Tumor Vaccine
Current Pharmaceutical Design Will Medicinal Cannabinoids Prove to be Useful Clinically?
Current Drug Therapy Molecular Imaging of Apoptosis In Vivo with Scintigraphic and Optical Biomarkers – A Status Report
Anti-Cancer Agents in Medicinal Chemistry Obesity in China: What are the Causes?
Current Pharmaceutical Design Gene Therapy: How to Target the Kidney. Promises and Pitfalls
Current Gene Therapy Flavonoids in Atherosclerosis: An Overview of Their Mechanisms of Action
Current Medicinal Chemistry